clinical trial · NCT07159126
A Study of DS3610a in Participants With Advanced Solid Tumor
Daiichi Sankyo·phase1·recruiting·n = 70
Solid TumorsMetastatic Solid TumorsDS3610a
brief summary
This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.
started
Oct 9, 2025
primary completion
Sep 1, 2028
completion
Feb 1, 2031
last updated
Dec 10, 2025
detailed description
This is a dose escalation study for participants with advanced or metastatic solid tumors. The primary objective of the study is to determine the Recommended Dose for Expansion (RDE), and to evaluate the safety, tolerability, PK, and preliminary efficacy of DS3610a in solid tumors.
official title
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol